RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+4.03%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.54B
AUM Growth
+$6.54B
(-1.1%)
Cap. Flow
+$38.9M
Cap. Flow
% of AUM
0.59%
Top 10 Holdings %
Top 10 Hldgs %
52.67%
Holding
82
New
10
Increased
17
Reduced
8
Closed
14
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$100M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$65.3M |
| 3 |
GE HealthCare
GEHC
|
$42M |
| 4 |
BBNX
Beta Bionics, Inc. Common Stock
BBNX
|
$40.4M |
| 5 |
uniQure
QURE
|
$35.6M |
Top Sells
| 1 |
Bruker
BRKR
|
$145M |
| 2 |
Axsome Therapeutics
AXSM
|
$132M |
| 3 |
89bio
ETNB
|
$40.1M |
| 4 |
Dyne Therapeutics
DYN
|
$36.9M |
| 5 |
Alkermes
ALKS
|
$22.2M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Globus Medical
GMED
$7.94B
| $82.4M | 1.26% |
1,125,000
+153,000
| +16% | +$11.2M |
|
27
Ultragenyx Pharmaceutical
RARE
$3.04B
| $61.8M | 0.95% |
1,707,402
-260,600
| -13% | -$9.44M |
|
28
GH Research
GHRS
$870M
| $60.7M | 0.93% |
5,499,769
+2,172,640
| +65% | +$24M |
|
29
Spyre Therapeutics
SYRE
$1.02B
| $58.4M | 0.89% |
3,621,996
| – | – |
|
|
30
uniQure
QURE
$954M
| $45.2M | 0.69% |
4,265,428
+3,361,803
| +372% | +$35.6M |
|
31
UroGen Pharma
URGN
$896M
| $42.4M | 0.65% |
3,834,794
| – | – |
|
|
32
GE HealthCare
GEHC
$33B
| $42M | 0.64% |
+520,000
| New | +$42M |
|
33
CG Oncology
CGON
$2.19B
| $41.7M | 0.64% |
1,701,216
| – | – |
|
|
BBNX
34
Beta Bionics, Inc. Common Stock
BBNX
$855M
| $40.4M | 0.62% |
+3,299,870
| New | +$40.4M |
|
35
Orchestra BioMed
OBIO
$147M
| $35.1M | 0.54% |
8,206,162
| – | – |
|
36
Stoke Therapeutics
STOK
$1.08B
| $34.1M | 0.52% |
5,123,525
| – | – |
|
37
Immatics
IMTX
$662M
| $31.2M | 0.48% |
6,909,510
+368,970
| +6% | +$1.66M |
|
38
Taysha Gene Therapies
TSHA
$791M
| $26.1M | 0.4% |
18,787,866
+10,115,236
| +117% | +$14.1M |
|
39
Verastem
VSTM
$585M
| $25.6M | 0.39% |
+4,245,476
| New | +$25.6M |
|
40
Xencor
XNCR
$594M
| $25.6M | 0.39% |
2,402,883
| – | – |
|
41
Arvinas
ARVN
$580M
| $23.4M | 0.36% |
3,334,308
| – | – |
|
|
LENZ
42
LENZ Therapeutics
LENZ
$1.12B
| $22.2M | 0.34% |
863,389
| – | – |
|
43
Replimune Group
REPL
$460M
| $20.1M | 0.31% |
2,065,010
| – | – |
|
|
ORKA
44
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $20M | 0.31% |
1,945,649
| – | – |
|
|
TEM
45
Tempus AI, Inc. Class A Common Stock
TEM
$13.3B
| $19.3M | 0.3% |
+400,000
| New | +$19.3M |
|
46
Glaukos
GKOS
$5.42B
| $18.7M | 0.29% |
+190,000
| New | +$18.7M |
|
|
47
Dyne Therapeutics
DYN
$1.92B
| $17.7M | 0.27% |
1,690,567
-3,528,074
| -68% | -$36.9M |
|
|
CRGX
48
DELISTED
CARGO Therapeutics
CRGX
| $16.8M | 0.26% |
4,124,859
| – | – |
|
49
Quest Diagnostics
DGX
$20.1B
| $16.8M | 0.26% |
+98,997
| New | +$16.8M |
|
|
CMPS
50
Compass Pathways
CMPS
$452M
| $15.8M | 0.24% |
5,538,168
+2,439,181
| +79% | +$6.98M |
|